Safety and Effectiveness of the Spiration Valve System in Air Leaks (VAST)
Phase: Pre-market Approval
Status: Not Recruiting
Purpose: To look at safety and efficacy of the investigational device, the Spiration Valve System (SVS) in treating patients with prolonged air leaks in the lungs lasting for more than five days
Study design: This is a multicenter, prospective, randomized, controlled study designed to evaluate treatment with the SVS as compared to standard chest tube drainage management and other standard-of-care interventions in the control group. Eligible subjects will be randomized to receive either Spiration Valves (investigational arm) or continue standard-of-care treatment (control arm)
Background: Air leak from the lungs is a post-operative complication that can arise from thoracic surgical operations, including lung volume reduction surgery for patients with emphysema. Prolonged air leaks last more than 5 days can significantly increase the length of stay in the hospital, infectious complications and treatment cost. The (SVS) offers a non-surgical, minimally invasive treatment for patients who have prolonged air leaks. One or more of these valves is placed in the airways that lead to the part of the lungs that are leaking air. The valves limit the amount of air that can reach the damaged parts of the lungs, but still allows mucus to clear out of these areas. It may provide benefits including better healing and shorter length of stay in a hospital.
Inclusion Criteria | Exclusion Criteria |
|
|
Principal Investigator
Ganesh Krishna, MD, PAMF
Sponsor
Spiration, Inc.
Contact
John Tejeda, Enterprise Senior Director for Clinical Research
Taft Center for Clinical Research
650-691-4894
John_Tejeda@elcaminohealth.org